An interventional study of 1.56 g L-Tryptophan and 1.56 g L-Leucine in Endocrine System Diseases, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Prevention
With this study the investigators investigate the effects of amino acids (tryptophan, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms and brain activation.
307 studies on the registry are indexed under Endocrine System Diseases; 52 are open to participants now.
This study's enrollment of 20 is below the median of 69 across 216 interventional studies indexed under Endocrine System Diseases.
Browse Endocrine System Diseases studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
Dietary Supplement: 1.56 g L-Tryptophan · Dietary Supplement: Tap water · Dietary Supplement: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) · Device: Nasogastric Tube
1.56 g L-Leucine in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
Dietary Supplement: 1.56 g L-Leucine · Dietary Supplement: Tap water · Dietary Supplement: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) · Device: Nasogastric Tube
50 g Xylitol in 300 mL tap water given via nasogastric tube
Dietary Supplement: 50 g Xylitol · Dietary Supplement: Tap water · Device: Nasogastric Tube
75 g Erythritol in 300 mL tap water given via nasogastric tube
Dietary Supplement: 75 g Erythritol · Dietary Supplement: Tap water · Device: Nasogastric Tube
75 g Glucose in 300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
Dietary Supplement: 75 g Glucose · Dietary Supplement: Tap water · Dietary Supplement: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) · Device: Nasogastric Tube
300 mL tap water given via nasogastric tube + after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
Dietary Supplement: Tap water · Dietary Supplement: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) · Device: Nasogastric Tube
Effect of aminoacids on cerebral blood flow measured by functional brain MRI
Time frame: changes from baseline to one hour after treatment
Effect of sugar alcohols on cerebral blood flow measured by functional brain MRI
Time frame: changes from baseline to one hour after treatment
Measurement of Plasma Glucose concentrations
Time frame: changes from baseline to three hours after treatment
Measurement of Plasma Insulin concentrations
Time frame: changes from baseline to three hours after treatment
Measurement of Plasma cholecystokinin concentrations
Time frame: changes from baseline to three hours after treatment
Measurement of Plasma Glucagon-like Peptide (GLP-1) concentrations
Time frame: changes from baseline to three hours after treatment
Measurement of Plasma PYY concentrations
Time frame: changes from baseline to three hours after treatment
Measurement of Plasma ghrelin concentrations
Time frame: changes from baseline to three hours after treatment
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland